NasdaqCM:CTIC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has CTI BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTIC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: CTIC's weekly volatility has increased from 19% to 31% over the past year.


Market Performance


7 Day Return

6.3%

CTIC

-0.2%

US Biotechs

1.8%

US Market


1 Year Return

364.1%

CTIC

21.2%

US Biotechs

20.4%

US Market

Return vs Industry: CTIC exceeded the US Biotechs industry which returned 21.2% over the past year.

Return vs Market: CTIC exceeded the US Market which returned 20.4% over the past year.


Shareholder returns

CTICIndustryMarket
7 Day6.3%-0.2%1.8%
30 Day6.0%5.4%6.0%
90 Day225.4%6.1%6.8%
1 Year364.1%364.1%23.2%21.2%23.2%20.4%
3 Year36.9%36.9%24.2%17.8%47.4%37.6%
5 Year-69.3%-69.3%9.7%2.2%91.9%70.8%

Long-Term Price Volatility Vs. Market

How volatile is CTI BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CTI BioPharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CTIC ($3.71) is trading below our estimate of fair value ($22.97)

Significantly Below Fair Value: CTIC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CTIC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CTIC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTIC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTIC is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is CTI BioPharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

31.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTIC's revenue (74.4% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: CTIC's revenue (74.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTIC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CTI BioPharma performed over the past 5 years?

26.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTIC is currently unprofitable.

Growing Profit Margin: CTIC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 26.2% per year.

Accelerating Growth: Unable to compare CTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: CTIC has a negative Return on Equity (-97.47%), as it is currently unprofitable.


Next Steps

Financial Health

How is CTI BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: CTIC's short term assets ($58.7M) exceed its short term liabilities ($14.5M).

Long Term Liabilities: CTIC's short term assets ($58.7M) exceed its long term liabilities ($1.8M).


Debt to Equity History and Analysis

Debt Level: CTIC's debt to equity ratio (7.9%) is considered satisfactory.

Reducing Debt: CTIC had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTIC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CTIC has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 11.4% each year.


Next Steps

Dividend

What is CTI BioPharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTIC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTIC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Adam Craig (54 yo)

3.67yrs

Tenure

US$1,702,367

Compensation

Dr. Adam R. Craig, M.D., Ph.D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Craig
President3.67yrsUS$1.70mno data
David Kirske
Executive VP3.17yrsUS$831.89k0%
$ 0
Bruce Seeley
Executive VP & COO3.17yrsUS$859.48k0.044%
$ 120.6k
Ed Bell
Senior Director of Investor Relations12.42yrsno datano data
Jim Fong
Senior Vice President of Global Operationsno datano datano data
Bruce Bennett
Senior Vice President Global Pharmaceutical Operationsno datano datano data
John Volpone
Senior Vice President of Strategic Operationsno datano datano data
Jennifer Smith
Senior Vice President of Biometrics2yrsno datano data

3.2yrs

Average Tenure

61yo

Average Age

Experienced Management: CTIC's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adam Craig
President3.67yrsUS$1.70mno data
Daniel Von Hoff
Chairman of Scientific Advisory Board7.33yrsno datano data
Laurent Fischer
Independent Chairman of the Board3.17yrsUS$165.35k0%
$ 0
David Parkinson
Independent Director3.42yrsUS$130.85k0%
$ 0
Matthew Perry
Independent Director4.83yrsUS$116.85k0.059%
$ 160.1k
Reed Tuckson
Independent Director9.17yrsUS$132.35k0.13%
$ 342.9k
Michael Metzger
Independent Director3.83yrsUS$143.85k0.027%
$ 74.6k

3.8yrs

Average Tenure

56yo

Average Age

Experienced Board: CTIC's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.2%.


Top Shareholders

Company Information

CTI BioPharma Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CTI BioPharma Corp.
  • Ticker: CTIC
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$273.600m
  • Shares outstanding: 73.75m
  • Website: https://www.ctibiopharma.com

Number of Employees


Location

  • CTI BioPharma Corp.
  • 3101 Western Avenue
  • Suite 800
  • Seattle
  • Washington
  • 98121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTICNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1997
0RLBLSE (London Stock Exchange)YesCommon StockGBEURMar 1997
CEPSDB (Deutsche Boerse AG)YesCommon StockDEEURMar 1997

Biography

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/25 00:22
End of Day Share Price2020/11/24 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.